bioRxiv ScienceSearch

bioRxiv · 10.1101/2021.03.26.437296

Machine-learning prediction of resistance to sub-inhibitory antimicrobial concentrations from Escherichia coli genomes

Abstract

Escherichia coli is an important cause of bacterial infections worldwide, with multidrug resistant strains incurring substantial costs on human lives. Besides therapeutic concentrations of antimicrobials in healthcare settings, the presence of sub-inhibitory antimicrobial residues in the environment and in the clinics selects for antimicrobial resistance (AMR), but the underlying genetic repertoire is less well understood. We used machine-learning to predict the population doubling time and growth yield of 1,432 genetically diverse E. coli expanding under exposure to three sub-inhibitory concentrations of six classes of antimicrobials from single nucleotide genetic variants, accessory gene variation and the presence of known AMR genes. We could predict cell yields in the held-out test data with an average correlation (Spearmans {rho}) of 0.63 (0.32 - 0.90 across concentrations) and cell doubling time with an average correlation of 0.47 (0.32 - 0.74 across concentrations), with moderate increases in sample size unlikely to improve predictions further. This points to the remaining missing heritability of growth under antimicrobials exposure being explained by effects that are too rare or weak to be captured unless sample size is dramatically increased, or by effects other than those conferred by the presence of individual SNPs and genes. Predictions based on whole genome information were generally superior to those based only on known AMR genes, and also accurate for AMR resistance at therapeutic concentrations. We also pinpointed genes and SNPs determining the predicted growth and thereby recapitulated the known AMR determinants. Finally, we estimated the effect sizes of resistance genes across the entire collection of strains, disclosing growth effects for known resistance genes for each strain. Our results underscore the potential of predictive modelling of growth patterns from genomic data under sub-inhibitory concentrations of antimicrobials, although the remaining missing heritability poses an issue for achieving the accuracy and precision required for clinical use. ImportancePredicting bacterial growth from genome sequences is important not only for a rapid characterization of strains in clinical diagnostic applications but for the identification of novel targets for drug discovery. Previous studies examined the relationship between bacterial growth and genotype in mutant libraries for laboratory strains, yet no study has so far examined the prediction power of genome sequences for bacterial growth in natural strains. In this study, we used a high throughput phenotypic assay to measure bacterial growth of a systematic collection of natural Escherichia coli strains and then employed machine learning models to predict bacterial growth from genomic data under non-therapeutic sub-inhibitory concentrations of antimicrobials that are common in nonclinical settings. Our results revealed a moderate to strong correlation between predicted and actual values for different antimicrobials concentrations. Furthermore, the quantified effect of resistance genes on bacterial growth indicate these genes are still effective at sublethal antimicrobial concentrations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Benkwitz-Bedford, S., Palm, M., Demirtas, T. Y., Mustonen, V., Farewell, A., Warringer, J., Moradigaravand, D., Parts, L.. 2021-03-28. Machine-learning prediction of resistance to sub-inhibitory antimicrobial concentrations from Escherichia coli genomes. https://doi.org/10.1101/2021.03.26.437296

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A conserved cysteine-histidine-glutamate metal site identifies DUF501 (Rv1025), an essential uncharacterised protein family of Mycobacterium tuberculosis, as a candidate metalloenzyme and drug target

A substantial fraction of the Mycobacterium tuberculosis proteome remains functionally uncharacterised. Rv1025, a 155-residue protein carrying the domain of unknown function DUF501 (Pfam PF04417), is essential by transposon mutagenesis and vulnerable by CRISPR interference, an attractive but neglected drug target, yet has never been functionally described. The family (4,370 proteins, no Gene Ontology term, no solved structure) is uncharacterised across all organisms and essential in three Actinobacterial genera. A Foldseek search of the AlphaFold model against complete structural databases finds no significant homolog, indicating a novel fold. The operon eno-divIC-Rv1025-ppx2 is conserved across the Actinobacteria phylum, yet AlphaFold-Multimer finds no direct complex between Rv1025 and its neighbour DivIC. Instead, conservation across 8,700 homologous sequences reveals a near-invariant Cys113-His115-Glu59 cluster forming a pocket. Holo AlphaFold3 predictions with Zn, Fe and Mn confidently place a divalent metal on this triad at 2.25-2.47 A; mutating the triad relocates the metal, and an independent backbone-geometry predictor recovers the same site, confirming specificity. The triad is universal across the family: present in all 1,472 near-complete bacterial sequences of the Pfam alignment, with no non-conservative substitution among the 2,228 sequences examined, a defining feature of bacterial DUF501 rather than a mycobacterial peculiarity. We propose that DUF501 is a metal-binding protein and candidate metalloenzyme, the first functional hypothesis for this family, whose conserved, essential metal pocket is a promising drug target. As the predictions build on a conservation-defined site within a fully computational study, they are supportive rather than proof of metal occupancy and warrant experimental validation.

microbiology

Mycoplasmal endosymbionts of Trichomonas vaginalis are associated with reduced risk for Chlamydia trachomatis endometrial infection in asymptomatic, coinfected, women.

Trichomonas vaginalis is a protozoan parasite that causes trichomoniasis, the most common curable non-viral sexually transmitted infection, and Chlamydia trachomatis is a bacterial pathogen that can ascend to the upper genital tract and cause pelvic inflammatory disease, infertility, and ectopic pregnancy. T. vaginalis harbors bacterial endosymbionts, including Candidatus Malacoplasma girerdii, an obligate symbiont, and Metamycoplasma hominis, which can live freely or symbiotically. In a 16S rRNA sequencing study of the cervicovaginal microbiome of women at high risk for chlamydial infection, Ca. M. girerdii abundance was one of 13 features predicting lack of chlamydial spread to the endometrium, despite no direct association between T. vaginalis infection and reduced chlamydial ascension. Investigating the relationship between these microorganisms further, we found that T. vaginalis vaginal abundance correlated positively with chlamydial burden in women whose infection was confined to the cervix, while a nonsignificant inverse relationship was seen in women with endometrial spread. Among participants with high chlamydial burden, Ca. M. girerdii was detected exclusively in women without endometrial infection. Both endosymbionts trended toward more frequent detection, and higher abundance, in coinfected women without endometrial spread, while M. hominis abundance correlated strongly with T. vaginalis burden in this group. These findings suggest that mycoplasmal endosymbionts of T. vaginalis, rather than T. vaginalis itself, are microbial factors limiting chlamydial ascension, and point to a three-way interaction between parasite, endosymbiont, and bacterial pathogen that shapes upper genital tract C. trachomatis infection risk.

microbiology

Understanding the physiological alterations of Vibrio cholerae upon exposure to L-ascorbic acid

The scourge of cholera remains a major global public health threat. It affects up to 4 million people worldwide and causes tens of thousands of deaths each year. The disease is experiencing a concerning resurgence in many parts of Africa, the Middle East, and Asia. To effectively tackle cholera and circumvent rising antimicrobial resistance, targeted biological and preventive approaches, complementing traditional rehydration, are urgently needed. In this regard, our group has demonstrated the efficacy of L-ascorbic acid in controlling the growth and pathogenesis of Vibrio cholerae in vitro. The present work further provides a mechanistic elucidation of the L-ascorbic acid-mediated physiological changes in V. cholerae and also bolsters such a non-antibiotic approach to control cholera.

microbiology